Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Catena

    - PMLiVE

    Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

    Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

    Uniphar

    - PMLiVE

    Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

    The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

    - PMLiVE

    MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy

    The severe neuromuscular disease affects approximately 2,500 people in the UK

    - PMLiVE

    NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

    Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

    - PMLiVE

    FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

    The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

    - PMLiVE

    FDA approves Italfarmaco’s Duvyzat as first nonsteroidal Duchenne muscular dystrophy drug

    The neuromuscular genetic disease is estimated to affect one in every 3,500 to 6,000 male births worldwide

    - PMLiVE

    Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatment

    The muscle-wasting disorder is estimated to affect one in every 3,500 male births worldwide

    - PMLiVE

    MHRA approves Santhera’s Duchenne muscular dystrophy drug Agamree

    The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

    EU flag

    EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

    The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

    - PMLiVE

    FDA approves Santhera’s Duchenne muscular dystrophy drug Agamree

    The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

    EU flag

    EMA endorses digital measure as primary endpoint in Duchenne muscular dystrophy trials

    The decision qualifies SV95C as an alternative to the widely used six-minute walking test

    - PMLiVE

    FDA grants accelerated approval to Sarepta’s Duchenne muscular dystrophy gene therapy

    The disease occurs in up to one in every 5,000 newborn males worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links